Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Cash from Operations rose 10636.1% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.1 million, marking a year-over-year increase of 8533.64%. This contributed to the annual value of -$148.6 million for FY2024, which is 2663.31% down from last year.
  • Latest data reveals that Seres Therapeutics reported Cash from Operations of $2.2 million as of Q3 2025, which was up 10636.1% from -$13.3 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Cash from Operations ranged from a high of $127.7 million in Q3 2021 and a low of -$76.6 million during Q1 2023
  • In the last 5 years, Seres Therapeutics' Cash from Operations had a median value of -$39.7 million in 2021 and averaged -$24.9 million.
  • The largest annual percentage gain for Seres Therapeutics' Cash from Operations in the last 5 years was 59386.07% (2021), contrasted with its biggest fall of 18930.11% (2021).
  • Quarter analysis of 5 years shows Seres Therapeutics' Cash from Operations stood at -$51.9 million in 2021, then dropped by 1.98% to -$52.9 million in 2022, then grew by 10.2% to -$47.5 million in 2023, then rose by 18.14% to -$38.9 million in 2024, then surged by 105.67% to $2.2 million in 2025.
  • Its Cash from Operations stands at $2.2 million for Q3 2025, versus -$13.3 million for Q2 2025 and $26.9 million for Q1 2025.